Voraxaze
Voraxaze ingredients
| Active ingredient | Strength |
|---|---|
| Glucarpidase | 1000 [USP'U]/1 |
What Voraxaze is used for
The FDA lists the approved uses on the official label (below). In the EU, glucarpidase is approved as Voraxaze for:
Voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Voraxaze
- Generic name
- Glucarpidase
- Made by
- BTG International Inc.
- Forms
- Injection, Powder, For Solution
- Given
- Intravenous
- Drug class
- Carboxypeptidase
- FDA approval
- Biologic licence (BLA) BLA125327
- On the US market since
- 2012
Official information
- Voraxaze prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Glucarpidase)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Voraxaze?
Voraxaze (Glucarpidase) is a specialist medicine made by BTG International Inc., approved by the US FDA.
What are the ingredients of Voraxaze?
Voraxaze contains Glucarpidase (1000 [USP'U]/1).
Is Voraxaze approved in Europe?
The same active substance is approved in the EU as Voraxaze.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA